glp-1 news november 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio glp-1 news november 2025 Patients

-cell-selective knockout of the GLP-1R in mice with impaired glucose tolerance after intraperitoneal injection of glucose and exogenous supplementation of GLP-1 did not induce insulin secretion, but glucose tolerance returned to normal after oral glucose, suggesting that the extra-islet GLP-1R plays a regulatory role in oral glucose tolerance (Smith et al., 2014)

Animal studies have shown fetal growth concerns at high exposures

The NHP and mice PK studies were conducted at Labcorp Early Development Laboratories Limited, Huntingdon, UK

Artificial Intelligence (AI) is transforming the obesity GLP-1 market by enabling personalized treatment strategies through patient profiling, predictive analytics, and biomarker identification

GLP-1 Agonists Marketed Drugs The Glucagon-like Peptide-1 (GLP-1) Agonists marketed drug section will provide detailed drug profiles of already approved therapies

Employers have largely attempted to avoid these cost increases, with a 2023 Accolade survey finding that approximately 60% of employers do not intend to cover GLP-1s in 2024